- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- Pembrolizumab, Epacadostat, Sunitinib, Pazopanib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Lenvatinib, Placebo for lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more
- Conditions
- Endometrial Neoplasms
- Interventions
- Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 827 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301, Observational cohort
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
- Conditions
- Huntington Disease, Parkinson Disease
- Interventions
- MindTrails
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Parkinson's Disease, Quality of Life
- Interventions
- Resonator Device
- Device
- Lead sponsor
- pico-tesla Magnetic Therapies, LLC
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Denver, Colorado • Englewood, Colorado + 3 more
- Conditions
- Carcinoma, Nonsquamous Non-small-cell Lung
- Interventions
- Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,003 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sacituzumab Govitecan, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 23
- States / cities
- Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
- Drug · Biological · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Parkinson's Disease
- Interventions
- Spinning Class, Yoga Class, Dance Class, No Exercise Class
- Behavioral · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- UC (Urothelial Cancer)
- Interventions
- Pembrolizumab, Epacadostat, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Orange, California • San Francisco, California + 19 more
- Conditions
- Endometrial Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 47
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Irvine, California + 42 more
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
- Conditions
- Parkinson's Disease
- Interventions
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 301 participants
- Timeline
- 2002 – 2003
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 27
- States / cities
- Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
- Conditions
- Parkinson's Disease
- Interventions
- Balance Training
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Parkinson Disease, Early Parkinson's Disease
- Interventions
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- Pembrolizumab, BCG
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2034
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
- Conditions
- Endometrial Neoplasms
- Interventions
- pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- apomorphine infusion
- Drug
- Lead sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 60
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more